Targretin oral (bexarotene oral) / ReXceptor - LARVOL DELTA

Efficacy and safety of Targretin capsule 75-mg alone or in combination with phototherapy in Japanese patients with Cutaneous T-cell Lymphomas (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: Nagoya City University Graduate School of Medical Sciences Department of Geriatric and Environmental Dermatology; Osaka City University Graduate Schoo | Unknown status ➔ Completed

Trial completion • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Efficacy and safety of bexarotene combined with phototherapy in Japanese patients with Cutaneous T-cell Lymphomas (clinicaltrials.gov) - P=N/A | N=25 | Completed | Sponsor: Nagoya City University Graduate School of Medical Sciences Department of Geriatric and Environmental Dermatology; Osaka City University Graduate Schoo | Unknown status ➔ Completed

Trial completion • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Reply to 'Caution in interpreting retrospective comparisons of acitretin and bexarotene in mycosis fungoides'. (PubMed, Br J Dermatol) - No abstract available

Journal • Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

Adverse events associated with systemic cutaneous T-cell lymphoma therapies: a narrative review. (PubMed, Front Med (Lausanne)) - "Peripheral neuropathy was the defining AE of brentuximab vedotin. Mogamulizumab was distinguished by mogamulizumab-associated rash, a treatment-emergent immune reaction that closely mimics CTCL progression. Bexarotene required proactive management of hypertriglyceridemia and central hypothyroidism...A recurring challenge is distinguishing cutaneous drug toxicity from CTCL progression, underscoring the importance of therapy-specific toxicity awareness. Standardized AE reporting and patient-centered outcome measures are needed to optimize long-term care in this population."

Adverse events • Journal • Review • Cutaneous T-cell Lymphoma • Dermatology • Dyslipidemia • Endocrine Disorders • Hematological Disorders • Hematological Malignancies • Hypertriglyceridemia • Infectious Disease • Lymphoma • Mucositis • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Pain • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

Caution in Interpreting Retrospective Comparisons of Acitretin and Bexarotene in Mycosis Fungoides. (PubMed, Br J Dermatol) - No abstract available

Journal • Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

Glis3 shapes pituitary patterning and TSH set‑point in zebrafish, modelling GLIS3‑associated congenital hypothyroidism (ETA 2026) - "HPT feedback was challenged with levothyroxine (LT4), triiodothyronine (T3), the TR agonist TRIAC, or the RXR agonist bexarotene. glis3 contributes to adenohypophyseal patterning and Pit1 lineage allocation during zebrafish organogenesis. Its deficiency expands thyrotrope and lactotrope populations, likely shifting the TSH set-point upward and reducing sensitivity to hormonal feedback and RXR-pathway modulation. These findings identify glis3 as a modulator of the central TH feedback set-point."

CNS Disorders • Endocrine Disorders

Oral mycosis fungoides. (PubMed, BMJ Case Rep) - "She had known MF treated with oral bexarotene, electron beam therapy and localised radiotherapy...Unfortunately, the patient succumbed to her disease 7 months after presentation to our unit. This case highlights that oral involvement can develop in MF and can have a significant impact on a patient's quality of life."

Journal • Cutaneous T-cell Lymphoma • Dermatology • Hematological Disorders • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Oral Cancer • Pain • T Cell Non-Hodgkin Lymphoma • CD8

Purvalanol A identified by in silico screening as treatment option for Multiple Sulfatase Deficiency (SSIEM 2026) - "Results from a high-throughput drug screen identified the third-generation retinoids tazarotene and bexarotene as compounds capable of correcting MSD pathology in vitro... The in-silico drug repurposing approach identified three candidate compounds for the treatment of MSD: bosutinib, purvalanol A, and purvalanol B. Subsequent in vitro testing revealed that only purvalanol A (PubChem ID 456214) increased multiple sulfatase activities in a concentration-and time-dependent manner across different genetic backgrounds and reduced elevated glycosaminoglycan subspecies in MSD fibroblasts... We demonstrate the effectiveness of an in silico drug repurposing approach in identifying a compound that reversed key features of MSD pathology in vitro. Despite these beneficial effects, early signs of toxicity may limit the potential of purvalanol A for repurposing in MSD. Further elucidating its mode of action may help identify alternative treatment strategies with a more favorable..."

Metabolic Disorders

Real-world cardiovascular safety profile of bexarotene for the treatment of mycosis fungoides. (PubMed, Clin Exp Med) - "These findings provide reassurance regarding the short- to intermediate-term cardiovascular profile of bexarotene when appropriate monitoring and management of lipid and thyroid abnormalities are maintained. However, longer follow-up is required to determine whether these metabolic effects influence long-term cardiovascular risk."

Journal • Real-world evidence • Cardiovascular • Congestive Heart Failure • Cutaneous T-cell Lymphoma • Dermatology • Dyslipidemia • Endocrine Disorders • Heart Failure • Hematological Malignancies • Hypertriglyceridemia • Lymphoma • Metabolic Disorders • Mycosis Fungoides • Myocardial Infarction • Oncology • T Cell Non-Hodgkin Lymphoma

Myeloid Cell-Specific Retinoid X Receptor Signaling Facilitates White Matter Repair and Stroke Recovery in Aged Mice. (PubMed, Stroke) - "Myeloid RXR signaling promotes long-term stroke recovery in aged mice of both sexes and engages anti-inflammatory and prorepair mechanisms. Bexarotene warrants further evaluation as a potential neurorestorative therapy for stroke."

Journal • Preclinical • Cardiovascular • Cognitive Disorders • Inflammation • Ischemic stroke • Solid Tumor

GZ21T as an emerging topical dermatologic therapy: A literature review. (PubMed, Dermatol Online J) - "In mycosis fungoides models, GZ17-6.02 increased apoptosis and enhanced tumor cell killing, including in combination with standard agents such as bexarotene. GZ21T represents a promising topical, multimodal therapeutic approach for inflammatory and premalignant or malignant skin disease. Further clinical studies are needed to confirm efficacy, define long-term safety, and establish its role relative to current standard therapies."

Journal • Review • Actinic Keratosis • Atopic Dermatitis • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Immunology • Mycosis Fungoides • Oncology • Pruritus • Skin Cancer

A machine learning-derived and functionally validated circadian rhythm signature predicts clinical outcomes and in silico drug sensitivity in colorectal cancer. (PubMed, Transl Oncol) - "The CRS represents a promising prognostic biomarker that reflects tumor immune status and genomic features, providing valuable insights for personalized treatment strategies in CRC."

Clinical data • Journal • Tumor mutational burden • Colorectal Cancer • Oncology • Solid Tumor • BHLHE40 • CD8 • TMB • TP53

Bexarotene alleviates aberrant activation of microglia in early life by regulating the RXRα-PPARγ-NF-κB axis. (PubMed, Eur J Pharmacol) - "In an in vitro microglial inflammation model, the anti-inflammatory effect of bexarotene was dependent on peroxisome proliferator-activated receptor γ (PPARγ), as inhibition of PPARγ attenuated its actions. These findings identify RXRα as a critical transcriptional regulator maintaining early microglial homeostasis and limiting inflammation and provide a theoretical basis for the application of bexarotene in the treatment of neuroinflammatory damage caused by early-life trauma."

Journal • CNS Disorders • Developmental Disorders • Inflammation • Mood Disorders • Psychiatry • IL1B • IL6 • PPARG

RXRα suppression drives hepatic metabolic and immune dysfunction in sepsis. (PubMed, EMBO Mol Med) - "Transcriptomic analyses show that the septic liver becomes partially resistant to pharmacological activation of RXRα with bexarotene...Loss of RXRα in hepatocytes reduces Kupffer cell numbers, resulting in bacterial dissemination and mortality, a phenotype reproduced in a genetic model of selective Kupffer cell ablation. Overall, RXRα maintains the hepatic macrophage niche, linking hepatocellular transcriptional competence to systemic antibacterial defense."

Journal • Infectious Disease • Septic Shock

1,25-Dihydroxyvitamin D Induces a NURR1-Tyrosine Hydroxylase Transcriptional Axis Modulated by Rexinoid/RXR Signaling in Parkinson's Disease-Relevant Human Neural Cell Models. (PubMed, Cells) - "In addition, bexarotene and its novel analogs, A41 and A55, induce NURR1 mRNA expression in U87 cells by 2.8-, 3.1-, and 4.8-fold, respectively, with A55 outperforming the parent compound at matched concentration. Because Parkinson's disease is characterized by the selective degeneration of dopaminergic neurons and impaired NURR1-dependent transcriptional programs, our findings identify a 1,25D/VDR-NURR1-RXR transcriptional axis as a previously underappreciated regulatory framework for studying TH gene expression and dopaminergic gene regulation in Parkinson's disease-relevant neural contexts."

Journal • Brain Cancer • CNS Disorders • Glioblastoma • Movement Disorders • Neuroblastoma • Oncology • Parkinson's Disease • Solid Tumor • NR4A2

Real-World Outcomes and Survival with Targeted and Established Systemic Therapies in Advanced-Stage Cutaneous T-Cell Lymphoma: An Updated PROCLIPI Analysis (BAD 2026) - P | "Brentuximab vedotin (BV), a CD30+ antibody conjugate, was approved for CD30+ cutaneous T-cell lymphoma in 2018...In survival analyses (n = 370), OS improved if a patient received mogamulizumab for any line vs. those who received other systemic (P = 0.008)...Bexarotene and ECP remain important systemic therapies. These data inform phenotype-directed sequencing and underscore the need for prospective comparative studies."

Clinical • Metastases • Real-world • Real-world evidence • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • CCR4 • TNFRSF8

RXR agonist increases newly characterized GM-CSF-producing B220+CD8αα intraepithelial T cells. (PubMed, Sci Rep) - "Consistently, the RXR agonist bexarotene increased GM-CSF-producing B220+CD8αα+ T cells without affecting other cytokines or CD8αβ+ T cells. These findings identify B220+CD8αα+ IELs as a spatially distinct source of GM-CSF in the epithelial layer and indicate that the RXR pathway specifically promotes the GM-CSF-producing program, potentially contributing to maintaining immune homeostasis in the small intestine."

Journal • Inflammation • CSF2 • IFNG • IL17A

Granulomatous Mogamulizumab-Associated Rash Mimicking Disease Progression in Erythrodermic Mycosis Fungoides (BAD 2026) - "Previous treatments included narrowband ultraviolet B, oral psoralen–ultraviolet A and bexarotene...Mogamulizumab was discontinued due to the severity of cutaneous involvement, and the patient was treated with topical clobetasol propionate and methotrexate 20 mg weekly, resulting in clinical improvement...Cutaneous side effects are commonly reported with mogamulizumab; however, cases of scalp damage with alopecia are rarer. Recognition of MAR is essential to avoid misdiagnosis and initiate inappropriate escalation of lymphoma-directed therapy."

IO biomarker • Alopecia • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Immunology • Lymphoma • Mycosis Fungoides • Oncology • Sezary Syndrome • CCR4 • CD2 • CD4 • CD7 • CD8 • TNFRSF8

RXR-Driven Molecular Dysregulation Drives Amyotrophic Lateral Sclerosis And Is Rescued By Bexarotene. (ENCALS 2026) - "RXR-mediated changes were conserved across human post-mortem tissue and multiple genetic models and species. Our preclinical work therefore establishes bexarotene, an EMA-approved RXR agonist, as a strong candidate for drug repurposing."

Amyotrophic Lateral Sclerosis • CNS Disorders • Gene Therapies • TARDBP

The Repurposed Drug Bexarotene Rescues ALS-Relevant Phenotypes In The Severe Thy1-TDP43 Mouse Model (ENCALS 2026) - "Notably, bexarotene treatment almost completely rescued motor neuron cell death in the Thy1-hTDP43 mice.Conclusion We show that bexarotene treatment ameliorates key ALS-relevant phenotypes in the Thy1-hTDP43 mouse model including improving body weight and motor function, protecting against motor neuron cell death and maintaining NMJ innervation. These findings highlight the potential of bexarotene as a repurposed therapy for ALS, suggesting that activation of the RXR pathway may be a viable strategy for ameliorating disease-related phenotypes."

Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders • TARDBP • THY1

Signaling through RXRb and its agonist, bexarotene, promotes neuron formation in Xenopus laevis embryos. (PubMed, Biol Open) - "Xenopus ectodermal explants therefore provide a simple and efficient tool to identify novel retinoid agonists that promote neuronal differentiation. The genes expressed in response to bexarotene are consistent with a pathway to neuronal differentiation allied to standard retinoid signalling."

Journal • Alzheimer's Disease • CNS Disorders • RXRB

A Macrophage/Monocyte-Related Four-Gene Signature for Prognostic Assessment of Uveal Melanoma: BTBD6, C2CD4B, CCL24, and S100A4. (PubMed, Hum Mutat) - "A significant negative correlation between RiskScore and the IC50 of XMD8-85, lapatinib, roscovitine, salubrinal, bexarotene, LFM-A13, FTI-277, and TGX221 chemotherapeutic agents was further noticed. In this study, we computationally identified genes associated with both disease progression and macrophage/monocyte-related characteristics in UVM and constructed a prognostic risk model with predicted immune infiltration patterns. These findings generate testable hypotheses that may inform future experimental studies on the immune mechanisms underlying UVM."

Biomarker • Gene Signature • Journal • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma • CD8 • S100A4

REAL-WORLD EFFECTIVENESS AND SAFETY OF TOTAL SKIN ELECTRON BEAM THERAPY IN ADVANCED CUTANEOUS T-CELL LYMPHOMAS: A REAL-WORLD SINGLE-CENTER EXPERIENCE. (EHA 2026) - "In erythrodermic cases, the integration of subsequent systemic therapy (e.g., mogalizumab, methotrexate, or low-dose bexarotene) significantly extended the time to next treatment (TNT) to 30 moths compared to 6 months for those without (p=0.001). (C) Overall survival (OS) for early-stage mycosis fungoides (IA-IIA) versus advanced-stage disease (IIB-IV). (D) Progression-free survival (PFS) by stage; early-stage patients had significantly longer PFS."

Clinical • Metastases • Real-world • Real-world effectiveness • Real-world evidence • Alopecia • Cutaneous T-cell Lymphoma • Dermatitis • Hematological Malignancies • Immunology • Lymphoma • Mycosis Fungoides • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=6 | Completed | Sponsor: Stanford University | N=12 ➔ 6

Enrollment change • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Effects of Systemic Bexarotene on Depression and Anxiety Like Behaviors in Rats Subjected to Chronic Unpredictable Mild Stress (EADV-Sp 2026) - "These findings indicated that bexarotene may provide potential therapeutic contribution in stress-related affective disorders through anti-inflammatory and neurotrophic mechanisms. Figure 3: Schematic overview of stress-ınduced neuroinflammation and impaired BDNF/TrkB–CREB1 signaling in the hippocampus and prefrontal cortex"

Preclinical • CNS Disorders • Cutaneous T-cell Lymphoma • Depression • Mental Retardation • Mood Disorders • Psychiatry • CREB1 • IL1B • TNFA